BBNX (Beta Bionics, Inc. Common Stock) Stock Analysis - News
Beta Bionics, Inc. Common Stock (BBNX) is a publicly traded Healthcare sector company. As of May 21, 2026, BBNX trades at $10.11 with a market cap of $418.88M and a P/E ratio of 0.00. BBNX moved +7.43% today. Year to date, BBNX is -65.81%; over the trailing twelve months it is -36.17%. Its 52-week range spans $8.80 to $32.71. Analyst consensus is strong buy with an average price target of $19.00. Rallies surfaces BBNX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in BBNX news today?
Beta Bionics Raises 2026 Guidance to 37–39% Growth, Adds 20 Sales Territories: Beta Bionics raised its new patient starts guidance to 37–39% growth driven by high 30%+ pharmacy channel adoption and expects a seasonal Q2 uptick. The company plans to add at least 20 new sales territories in 2026 while reporting a one-time gross margin tailwind in Q1.
Beta Bionics Raises 2026 Guidance to 37–39% Growth, Adds 20 Sales Territories: Beta Bionics raised its new patient starts guidance to 37–39% growth driven by high 30%+ pharmacy channel adoption and expects a seasonal Q2 uptick. The company plans to add at least 20 new sales territories in 2026 while reporting a one-time gross margin tailwind in Q1.
Does Rallies summarize BBNX news?
Yes. Rallies summarizes BBNX news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is BBNX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for BBNX. It does not provide personalized investment advice.
